The FDA has approved the use of Ibrance (palbociclib) together with trastuzumab, with or without pertuzumab, plus hormone therapy as a maintenance treatment for adults with hormone receptor–positive, HER2-positive advanced or metastatic breast cancer after initial treatment. The approval is based on results from the phase 3 PATINA Trial, which enrolled 518 patients. The study […]
After nearly four decades of research, scientists at the Mayo Clinic have uncovered the molecular structure of protein kinase C beta (PKCβ), an important protein that helps regulate cell growth and has been linked to diseases such as cancer and Alzheimer’s. The breakthrough, published in the journal Nature Communications, was made possible by producing the
Researchers are studying how colorectal cancer begins before tumors develop. Using Lynch syndrome, an inherited condition that can raise colorectal cancer risk to as high as 80%, they explored how the immune system responds to early cancer-related changes. In a study published in the journal Nature Communications, scientists analyzed blood samples from 277 participants and
Blood Test May Help Detect Colorectal Cancer Risk Early in Lynch Syndrome Read More »
Patients with previously treated metastatic colorectal cancer may benefit from a new combination therapy of zanzalintinib and the immunotherapy drug Tecentriq, according to results from the Phase 3 STELLAR-303 trial. The study enrolled 901 patients whose cancer had progressed after standard treatments. Among all patients in the trial, the combination reduced the risk of death
A first-in-human Phase 1 study presented at the 2026 EHA Congress has reported encouraging results for CT0596, an off-the-shelf CAR T-cell therapy designed for patients with heavily pretreated relapsed or refractory multiple myeloma and primary plasma cell leukemia. Unlike traditional CAR T-cell treatments that are made from a patient’s own cells, CT0596 uses donor cells
Off-the-Shelf CAR T-Cell Therapy Shows Promising Early Results in Multiple Myeloma Read More »
The European Commission has approved the antibody-drug conjugate Trodelvy as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not eligible for PD-(L)1 inhibitor therapy. The approval is based on results from the Phase 3 ASCENT-03 trial, which showed that Trodelvy reduced the risk of disease progression or death
Researchers have identified a promising new way to weaken pancreatic cancer by targeting a protein called IL1RAP. Pancreatic tumors depend on an inflammatory network within their surrounding environment to grow, evade the immune system, and resist treatments such as chemotherapy and immunotherapy. IL1RAP acts as a key control point in this network, and blocking it
New Trial Targets Inflammation to Improve Pancreatic Cancer Treatment Read More »
A Phase II multicenter study in China has found that the chemotherapy combination of nab-paclitaxel and S-1 (SnP) may be an effective and well-tolerated treatment for patients with locally advanced pancreatic cancer. The regimen could provide an alternative for patients who are unable to tolerate more intensive therapies such as mFOLFIRINOX. Among 60 patients with
For patients with KRAS-mutant metastatic colorectal cancer whose disease progresses after two lines of treatment, third-line therapies can extend survival, but the benefits are often measured in months. As a result, doctors must carefully weigh treatment effectiveness, side effects, and quality of life when selecting therapy. Two commonly used options are trifluridine/tipiracil (Lonsurf) plus bevacizumab
The FDA has granted full approval to the cell therapy afamitresgene autoleucel (Tecelra) for adults and children aged 12 years and older with unresectable or metastatic synovial sarcoma. The approval expands on the drug’s accelerated approval in August 2024 by adding adolescent patients to the eligible population. The treatment is intended for patients whose cancer
FDA Approval to Tecelra for Synovial Sarcoma Read More »